Norflurazepam Powder

€ 40,00

Norflurazepam Powder is described as a laboratory research material associated with N-desalkylflurazepam, a benzodiazepine metabolite belonging to the 1,4-benzodiazepine family. Raw Lab Chems identifies this material exclusively for controlled chemical identification, chromatographic characterization, spectroscopic investigation, and analytical reference comparisons.

The supplied information includes claims concerning purity, independent testing, batch traceability, and specialized packaging. These specifications require supporting batch-specific documentation before they can be considered verified.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-S-12507 Category:
Description

Norflurazepam Powder 1g – N-Desalkylflurazepam Research Material

Product Overview

Norflurazepam Powder is described in the supplied information as a laboratory research material associated with N-desalkylflurazepam, a compound belonging to the 1,4-benzodiazepine family.

Norflurazepam is identified in the source as a metabolite of flurazepam, making it relevant to the chemical classification and analytical identification of benzodiazepine-related substances.

Its molecular identity provides a basis for analytical investigations involving structural comparison, chromatographic behavior, and spectroscopic characterization.

Raw Lab Chems presents the material exclusively within a Research Use Only framework.

The supplied source describes a white to off-white crystalline powder intended for controlled laboratory examination.

However, the stated physical presentation does not independently establish the actual chemical identity, purity, crystalline structure, or composition of the material.

The source also characterizes the preparation as laboratory-grade and refers to independent analytical verification and controlled manufacturing conditions.

These descriptions remain supplier-provided claims until supported by documentation associated with the actual batch.

No clinical, therapeutic, diagnostic, dietary, or consumer-oriented application is represented by this description.

Chemical Identity & Classification

Norflurazepam is identified in the supplied source as N-desalkylflurazepam.

The compound belongs to the 1,4-benzodiazepine class and is described as a metabolite of flurazepam.

Its desalkylated molecular structure distinguishes it from the parent compound.

The supplied source provides the following chemical-reference information:

  • Chemical name: Norflurazepam
  • Alternative name: N-Desalkylflurazepam
  • Chemical classification: 1,4-Benzodiazepine derivative
  • Reported CAS Registry Number: 2886-65-9
  • Reported molecular formula: C15H10ClFN3O
  • Reported molecular weight: 287.72 g/mol

These identifiers are reproduced from the supplied information and do not independently verify the composition of the actual product.

The reported molecular formula and molecular weight require verification. The supplied formula C15H10ClFN3O corresponds to an approximate formula mass of 303.72 g/mol, rather than the reported 287.72 g/mol.

The source does not provide an independent structural report resolving this discrepancy.

The precise chemical identity and associated molecular data should therefore remain provisional until authoritative documentation is available.

Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound.

Chemical & Physical Characteristics

The supplied product is described as a white to off-white fine crystalline powder.

No product-specific physical inspection record, microscopy report, diffraction dataset, or other evidence was provided to establish its actual appearance or crystalline state.

The stated physical form therefore remains a source-provided description.

Norflurazepam’s classification within the benzodiazepine family provides a basis for structural comparison with related compounds and metabolites.

However, structural similarity does not establish identical physical properties, analytical behavior, stability, or impurity profiles.

The source references solubility characteristics and stability under analytical conditions as areas of laboratory investigation.

No verified melting point, quantitative solubility profile, particle-size distribution, crystalline polymorph, density, or hygroscopicity measurement was supplied.

These characteristics should not be inferred from the compound name or chemical family.

The source recommends freezer storage at −20°C with protection from light and moisture.

No validated stability study, degradation profile, or experimentally established shelf-life specification accompanied this recommendation.

Researchers should distinguish general storage guidance from verified stability data associated with a particular batch.

Purity & Analytical Verification

The supplied description claims purity of at least 98%, characterized as typical and determined by HPLC.

However, no actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.

Accordingly, the stated purity threshold is not independently confirmed for the material described here.

The source identifies HPLC, mass spectrometry, NMR spectroscopy, and LC-MS/MS as analytical techniques associated with benzodiazepine-metabolite investigation.

Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.

However, naming an analytical technique does not establish that it was performed on the actual product.

The discrepancy between the supplied molecular formula and molecular weight makes independent identity confirmation particularly important.

The source also references chromatographic separation, positive-ion mass spectrometry, and analytical stability assessment as research topics.

These references describe possible analytical investigation areas rather than validated performance characteristics of the supplied material.

Any reported purity or identity result should be evaluated against the actual sample, method documentation, reference materials, and relevant analytical limitations.

No certified reference-material status or independently established purity specification is asserted.

Quality Control & Batch Integrity

The supplied source claims that individual batches undergo third-party testing and are supported by Certificates of Analysis.

It also describes batch traceability, verification of identity and purity, and testing for residual solvents and homogeneity.

No actual certificate, laboratory accreditation record, manufacturing audit, quality-system documentation, or batch-specific testing report accompanied these statements.

They therefore remain unverified supplier claims.

For reproducible laboratory investigation, useful documentation may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.

Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.

The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.

Likewise, the description does not independently demonstrate compliance with a particular quality-management certification.

Claims of consistent purity, identity, homogeneity, or manufacturing quality should be supported by actual analytical records rather than inferred from catalog terminology.

Safety, Handling & Laboratory Precautions

Norflurazepam is described as a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling.

Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.

Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.

The compound’s relationship to flurazepam does not establish safety for human or veterinary exposure.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.

Because the actual purity and chemical identity have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.

The powder presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes resealable inert packaging, thermal protection, appropriate chemical labeling, and professional handling during transportation.

No packaging-validation study, verified container specification, or actual shipment-condition record accompanied these claims.

The source recommends storage at −20°C in a desiccated environment protected from light and moisture.

No validated stability data was provided to establish that this temperature is necessary or sufficient for a particular shelf life.

The source additionally claims that packaging and transportation arrangements meet IATA and DOT requirements.

No shipment classification, carrier documentation, or compliance record was supplied to substantiate those statements.

Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.

The unresolved molecular identity information should also be recorded rather than replaced with an assumed specification.

Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.

Intended Research Use & Market Positioning

The supplied scientific context places norflurazepam within analytical research involving benzodiazepine metabolites, chemical characterization, structural comparison, and forensic identification.

Its relationship to flurazepam provides a basis for comparing chemical-reference information associated with parent compounds and metabolites.

The source also references chromatographic separation, mass-spectrometric fragmentation, and spectroscopic characterization as areas of laboratory investigation.

These references describe analytical research contexts and do not establish any human-use application.

For comparative chemical-catalog research, Raw Lab Chems also lists Norflurazepam Pellets and Norflurazepam Blister.

These listings identify alternative named product presentations but do not establish equivalent purity, formulation, content uniformity, or analytical characteristics.

The supplied Norflurazepam Powder catalog reference identifies the product presentation discussed here.

These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.

Ordering, Availability & Fulfillment

The supplied source describes worldwide shipping, discreet packaging, tracking, thermal protection, and transportation through compliant carriers.

No current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided.

Consequently, no specific availability, delivery, customs-clearance, transportation-compliance, or temperature-control guarantee is asserted.

Benzodiazepine-related compounds may be subject to controlled-substance or analog legislation.

Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.

Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.

Research-only labeling does not establish an exemption from controlled-substance regulations.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Norflurazepam is described as a benzodiazepine-related compound whose legal classification may vary by jurisdiction.

Acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance, analog, or other chemical regulations.

Researchers and institutions remain responsible for determining legal requirements and obtaining any necessary authorizations.

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Norflurazepam Powder”
Shipping & Delivery